Mer­ck, Vi­a­tris agree to set­tle patent feud sur­round­ing di­a­betes drugs

The dis­pute be­tween Mer­ck and Vi­a­tris over the patent rights for block­buster di­a­betes drugs Janu­via and Janu­met is over — so long as a judge signs off.

At­tor­neys for both Mer­ck and My­lan Phar­ma­ceu­ti­cals — now a part of Vi­a­tris — re­quest­ed last week that the dis­trict court in West Vir­ginia en­ter a fi­nal judg­ment in the case (1:19-cv-00101-IMK) up­on re­mand from the Unit­ed States Court of Ap­peals for the Fed­er­al Cir­cuit, a court that has spe­cial ap­pel­late ju­ris­dic­tion over cer­tain types of cas­es. These cas­es in­clude patents, trade­marks and gov­ern­ment con­tracts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER